There is a need for increased knowledge about endogenous sex hormone levels and clinical outcomes of risk/benefit. Immunoassays have poor specificity to reliably measure low steroid concentrations in elderly.
B
efore the age of 50 yr, the incidence of cardiovascular disease (CVD) is considerably lower in women than men. After menopause, the CVD incidence in women rapidly increases (1) to reach that of men, after 1-2 decades. The CVD incidence is higher in post-compared with premenopausal women at any age (2) . This suggests a protective effect of female sex steroids on the cardiovascular system, which is in line with numerous results from basic research (3) . Previous findings suggest that even subtle differences in serum estrogen concentrations, within the normal range for elderly, are positively associated with bone mass and negatively with fracture risk (4) . Endogenous sex steroid concentrations have also been associated with bone mineral density in men (5) , metabolic risk factors for CVD (6) , common carotid artery (CCA)-intimamedia thickness (IMT) (7-10) and prevalent CVD (11), and the risk of CVD events (12). However, conflicting results in previous reports might in part be caused by differences in mean age of the populations and high crossreactivity of commercial immunoassays for analysis of low endogenous concentrations of sex steroids, especially androgens in elderly women (13, 14) .
We recently developed highly sensitive and specific liquid chromatography-tandem mass spectrometry (LC-MS/ MS) methods, enabling identification and quantification of a large number of steroids in small sample volumes (15). The LC-MS/MS methods are superior to conventional immunoassays to assess low concentrations of sex steroids, e.g. androgens in elderly women. Tandem mass spectrometry methods have also been used as reference when evaluating more conventional direct and indirect methods for assessment of serum 17␤-estradiol (E2) (14) . According to the North American Menopause Society position statement in 2007, there is a need for increased knowledge about effects of endogenous concentrations of estradiol and/or estrone (E1) on clinical outcomes of risk and/or benefit (16). The aim of the present study was to evaluate associations between concentrations of endogenous plasma steroids and intermediates of the pathway of steroids biosynthesis in relation to prevalent CVD in 70-yrold women and men, using LC-MS/MS methods.
Subjects and Methods

Study population
All subjects participated in the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) (see www.medsci.uu.se/ pivus/pivus.htm). Eligible for the PIVUS study were all subjects aged 70 yr living in the community of Uppsala, Sweden. They were invited in a randomized order from April l, 2001 , to June 2004. The subjects were invited within 1 months of their 70th birthday. Of 2025 subjects invited, 1016 subjects were included in PIVUS. A group of 202 subjects (107 women and 95 men), from the 1016 70-yr-olds in PIVUS, were evaluated with regard to endogenous sex steroids. These were consecutive subjects returning in an ongoing follow-up and investigated with high-frequency carotid ultrasound. Women with current or previous menopausal hormone therapy (n ϭ 35) were excluded from the main analysis, thus 167 participants remaining: 72 women and 95 men (Tables 1, 2 ).
All subjects underwent a physical examination and recorded any medical history of coronary heart disease [CHD; myocardial infarction (MI), angina pectoris, coronary bypass, or balloon angioplasty], heart failure, stroke, and hypertension. CVD was defined as the presence of CHD, heart failure, or stroke but excluding subjects with hypertension only. CHD outcomes were defined by the International Classification of Diseases, 10th revision, codes described previously (17). Among the women, 10 had prevalent CVD, and among the men there were 18 with prevalent CVD. Plasma samples were collected in the morning and stored at Ϫ70 C until analysis. Samples were transported between participating centers packed on dry ice. Eleven steroids were quantified, using high-sensitivity LC-MS/MS assays at ARUP laboratories (Salt Lake City, UT) (18 -20). Each subject gave informed consent to the study. The study was approved by the Ethics Committee of Uppsala University (Uppsala, Sweden).
Reagents and standards
Testosterone (T), E1, E2, pregnenolone (Pregn), 17-hydroxypregnenolone (17OHPregn), 17-hydroxyprogesterone (17OHProg), 11 deoxycortisol (11DC), hydroxylamine, formic acid, trifluoroacetic acid, dansyl chloride, and sodium carbonate were purchased from Sigma Chemical Co. (St. Louis, MO). Androstenedione (A4), dehydroepiandrosterone (DHEA), and dihy- 
LC-MS/MS methods
Concentration of steroids in plasma was determined using LC-MS/MS methods. Estrogens were analyzed as dansyl derivatives (18); ketosteroids were analyzed as oxime derivatives (19, 20) . The HPLC system consisted of series 1200 HPLC pumps (Agilent, Santa Clara, CA), 10-port switching valve, a vacuum degasser, and an autosampler HTC PAL (LEAP Technologies, Carrboro, NC). An API 4000 (Applied Biosystems/MDS SCIEX, Foster City, CA) tandem mass spectrometer was used in the positive ion mode with TurboIonspray ion source. The analytic procedures are extensively described elsewhere (15, 18 -20) . The quadrupoles Q1 and Q3 were tuned to unit resolution, and the mass spectrometer conditions were optimized for maximum signal intensity and specificity in every sample. Two mass transitions were monitored for each steroid and its IS. Concentrations of each steroid were determined using the primary mass transitions; specificity of the analysis for each steroid was evaluated by comparing concentrations determined using the primary and the secondary mass transitions of each steroid and its IS (21). Quantitative data analysis was performed using Analyst 1.4.2 software (Applied Biosystems/MDS SCIEX). The assays showed within-run variation less than 10% and between-run variation less than 12% (15, 18 -20) . Calibration curves were generated with every set of samples using six calibration standards; three quality control samples were included with every set of samples.
Statistical analysis
Comparison between study groups and between sexes was carried out using nonparametric tests, Wilcoxon two-sample test. Fisher's exact test was used for comparisons of diagnoses between men and women. The distributions of the variables were tested with Shapiro-Wilks' test where a test statistic above 0.95 implied a normal distribution. In case of a lower test statistic, a logarithmic transformation was performed. All variables were normally distributed after logarithmic transformations. The relations between CVD and hormones were further examined with univariate and multiple logistic regression models from which standardized odds ratios with P values were presented. A standardized odds ratio shows the effect of an increase of 1 SD of a specific hormone with regard to prevalent CVD risk. Thus, standardized odds ratios simplify comparisons between effects of hormones with different scales or different dispersions. E3 was not included in the logistic regression because of very low concentrations, close to limit of quantitation. A two-sided P Ͻ 0.05 was considered a statistically significant result. All statistical analyses were performed with the statistical program packages JMP and SAS (SAS Institute Inc., Cary, NC). All authors have read and agree to the manuscript, as written.
Results
Subject characteristics
Among women, those with prevalent CVD had significantly higher weight, body mass index (BMI) and waist circumference. There were no significant differences between the sexes with regard to cardiovascular diagnosis and cardiovascular risk factors (Tables 1, 2 ).
Subjects without prevalent CVD
Men, compared with women, had significantly higher concentrations of plasma; 17OHPregn; 17OHProg; A4; T; DHT; E2; and higher A4 to DHEA, T to A4, E2 to E1 ratios and E2 to SHBG. Women had significantly higher concentration of SHBG and E2 to T, DHEA to 17OHPregn and A4 to 17OHProg ratios (Table 3) . Similar results were obtained in subjects with no medications (n ϭ 75). Thus, all significant differences remained, except for E2 to SHBG in men and SHBG in women.
Subjects with prevalent CVD
Men with prevalent CVD, compared with those without, had significantly lower concentrations of 17OHProg (P Ͻ 0.01) and higher E3 and E2 to T ratio. Women with prevalent CVD had lower concentrations of Pregn, 17OHPregn (P Ͻ 0.001), DHEA, and 17OHPregn to Pregn ratio but higher ratios of DHEA to 17OHPregn, A4 to DHEA, E2 to T, E2 to E1, and E2 to SHBG (Table 3) . The aromatase indices E1 to A4 and E2 to T, illustrating the CYP19 enzyme activities, were numerically higher in both in men and women with prevalent CVD and significantly so for the E2 to T ratio (P Ͻ 0.05, Table 3 ).
Adjustment for covariates
Adjustment for statin use or simultaneous adjustment for statin use, BMI, and current smoking yielded similar results. Women with current or previous menopausal hormone therapy excluded (n ϭ 35). Median values (range) are given; nonparametric statistics are used. CVD includes CHD (MI, angina pectoris, coronary bypass, or balloon angioplasty), heart failure, and stroke but excludes hypertension only. SHBG is in nanomoles per liter (sample required for this test is serum); as recommended by the vendor, values were corrected by factor 1.6 to compensate for performing the measurements in plasma samples. Note: E3, very low concentrations, close to the limit of quantitation and therefore not included in the logistic regression analysis.
In subjects without prevalent CVD, asterisk indicates significantly higher plasma concentrations compared with the opposite sex.
Thus, in men, after the latter adjustments, all previously significant findings with regard to prevalent CVD remained significant. Stronger significance levels were found for 17OHProg, E3, and the ratio E2 to T. In addition, significantly lower levels were found for 17OHPregn (P ϭ 0.048), 17OHPregn to Pregn ratio (P ϭ 0.02), higher values for A4 to 17OHProg ratio (P ϭ 0.020), E1 to A4 ratio (P ϭ 0.013), and borderline significance for E2 (P ϭ 0.056). In women, however, after adjustment for the same covariates, some previously significant findings disappeared or got weaker. However, lower 17OHPregn, DHEA, and 17OHPregn to Pregn ratio and higher A4 to DHEA ratio remained significant. The 17OHProg to 17OHPregn ratio became significantly higher (P ϭ 0.016) in women with prevalent CVD. After adjustment, both the aromatase indices, E1 to A4 and E2 to T ratios, became significant in men, whereas none of them was significant in women (Table 3) .
Univariate logistic regression
Univariate analysis confirmed the importance of single androgen precursors and androgens and product to precursor ratios (enzyme activities) with regard to prevalent CVD; in women there were lower Pregn adjusted odds ratio of 0.31, 95% confidence interval (0.11-0.90) (P ϭ 0.006); 17OHPregn, 0.18 (0.06 -0.61) (P ϭ 0.006); 17OHProg and DHEA in women and in men lower 17OHProg and marginally lower 17OHPregn in men. Furthermore, there were higher 17OHPregn to Pregn, DHEA to 17OHPregn, A4 to DHEA, and E2 to E1 ratios in women and higher E2 to T and marginally higher A4 to 17OHProg ratios in men (Table 4) .
Multivariate logistic regression
A model including single steroids, excluding estrogens and 11DC (model 1) confirmed the importance of lower17OHPregn in women and lower 17OHProg in men (Table 5) . A model including ratios toward synthesis of androgens indicated the importance of increased DHEA to 17OHPregn and A4 to DHEA ratios (marginally) in women and 17OHProg to 17OHPregn ratio in men (Table 5) . Excluding the path through 17OHProg to 17OHPregn (model 3) revealed similar results as in model 2 in women, whereas in men the significance for A4 to DHEA ratio was lost.
Discussion
To our knowledge this is the first report using high-sensitivity LC-MS/MS for quantitative analysis of several endogenous steroid hormones in the elderly. Prevalent CVD was associated with indications of lower androgen precursors, increased aromatase activity, and higher estrogen levels in both sexes. The association between low androgen precursors, most likely consumed, and increased enzyme activity toward synthesis of androgens were supported in logistic regression analysis. After adjustment for statin use, BMI, and smoking habits, the findings remained or got stronger in men, with additional hormones and ratios becoming significant, whereas in women some previously significant differences were lost. The differential effects of adjustments in men and women might be true dif- ferences in effects of these covariates between sexes or influenced by the lower number of prevalent CVD in women. Women with prevalent CVD had significantly lower pregnenolone, 17OHPregn, and DHEA combined with significantly higher ratios for enzyme steps after Pregn (also after adjustment), indicating that more is pushed forward toward androgens, the substrates for estrogen synthesis (Fig. 1) . Furthermore, women have lower concentrations of precursors (androgens) for estrogen synthesis than men. Therefore, the high E2 to E1 ratio in women with prevalent CVD might indicate an aim for synthesis of E2, the more potent form of estrogens. Thus, in women with prevalent CVD, all E2 to E1 and E2 to T ratios and E2 to SHBG were higher (Table 3) . Together these findings indicate a consumption of androgen precursors early in the pathway toward synthesis of androgens that are aromatized to estrogens, especially the potent E2.
Men with prevalent CVD had significantly lower 17OHProg, lower 17OHPregn, and 17OHPregn to Pregn ratio, significantly so after adjustment. In contrast, the A4 to 17OHProg ratio and aromatase activity (CYP19), both E2 to T and E1 to A4 ratios, were significantly higher, indicating a push toward estrogen synthesis also in men with prevalent CVD (Table 3) . Taken together, our results suggest a common or similar reaction to vascular disease in both women and men, aimed to increase androgens to be available for estrogen synthesis with indications for increased aromatase activity and estrogen levels in both sexes.
When comparing our results with those from previous reports, associations between endogenous steroid hormones and prevalent conditions in the form of CVD, CCA-IMT, or short-term follow-up of carotid-IMT are generally in agreement with our results. In contrast, reports studying associations between steroid hormones and prospective outcome, incidence of CVD events often are contrary to our results. Thus, in agreement with our results, in a study in women early after menopause, concentrations of endogenous steroid precursors and androgens seemed beneficial for carotid artery atherosclerosis, prevalent CCA-IMT (7, 22) . In the Swedish part of the large Mr. Osteoporosis study, low concentrations of testosterone and high concentrations of estradiol were associated with prevalent lower-extremity peripheral arterial disease in men with a mean age of 75 yr (11). In a Norwegian study on 1482 men, aged around 60 yr, androgens (total testosterone) were inversely associated with prevalent carotid atherosclerosis (age adjusted CCA-IMT) (8). Further- Women with current or previous menopausal hormone therapy were excluded (n ϭ 35). Adj. OR, Adjusted odds ratio; CI, confidence interval. a CVD includes CHD (MI, angina pectoris, coronary bypass, or balloon angioplasty), heart failure, or stroke but excludes hypertension only.
FIG. 1.
Biosynthesis of steroid hormones of the cholesterol pathway. Steroids with underlined names were analyzed using LC-MS/MS methods.
more, in a study from western Sweden using carotid-IMT, serum estradiol concentrations were found to be an independent predictor of progression of carotid IMT over a 3-yr period in men with a mean age of 58 yr (9) . Furthermore, in agreement with earlier reports, elderly men had higher concentrations of not only androgens but also estrogens, compared with women (23).
Higher estrogen concentrations in elderly men result from the slow decline of androgens by aging and thereby greater availability of androgen precursors for aromatization to estrogens in elderly men. Seemingly in contrast to our results, a long prospective evaluation from Framingham found that higher endogenous concentrations of estradiol was associated with lower risk of CVD events during a 10-yr follow-up of 2084 men in their mid-50s (12). Furthermore, higher endogenous serum E2 and SHBG concentrations in 89 postmenopausal women (mean age, 62 yrs) have been associated with slower progression of subclinical atherosclerosis, assessed by CCA-IMT (10), in contrast to findings in 58-yr-old men over a 3-yr period (9) . Furthermore, a recent study indicated lower risk of CVD event in women receiving low-dose vaginal estrogen therapy (24). Thus, some of the conflicting results between previous reports appear to result from differences in the analytical approach: whether hormone levels are tested against prevalent conditions, i.e. prevalent CVD/IMT or analyzed prospectively, with regard to incidence of CVD events or changes in carotid-IMT. Together these observations strengthen our proposed hypothesis (below) that our results might image an endogenous response of the body to a developing atherosclerotic process.
Effects of differences in the delta 5 pathway affecting endogenous DHEA sulfate [DHEA(S)] levels might be important for CVD risk. In agreement with our findings, Fukui et al. (25) found significant negative associations between DHEA(S) and prevalent carotid IMT and plaque score. Furthermore, in obese normotensive premenopausal women, DHEA was negatively associated with prevalent carotid IMT (26). Again, in contrast to our findings, a prospective evaluation with regard to CVD risk factors found that baseline DHEA(S) was significantly associated with incidence of CVD risk factors (systolic blood pressure, diastolic blood pressure, and smoking), indicating increased CVD risk (27). Thus, also here we find similar differential associations, largely depending on whether steroid hormone levels are tested against prevalent conditions or prospectively, e.g. incidence of CVD.
Poor specificity and performance of the commonly used immunoassays for analysis of low steroid levels in elderly (13, 14, 28) might be another reason for contradictory findings between studies. High-sensitivity LC-MS/MS methods used in the present study are more suitable for measuring low concentrations of endogenous steroids commonly found in postmenopausal women and elderly men (15, 18 -20) .
In postmenopausal women, low endogenous concentrations of sex hormones (within the normal postmenopausal range) have been associated with low bone mass and increased fracture risk (4) . We have previously shown that treatment using extremely low dose of parenteral estradiol (Estring 7.5 g per 24 h) given to elderly women (not increasing serum estradiol concentrations) have systemic effects and positively affect bone markers, bone density (29), and serum lipid profiles (30). Furthermore, in a recent report, use of low-dose estrogen regimens in the form of vaginal estrogens was associated with markedly lower risk of myocardial infarction (24). Thus, even subtle differences in endogenous levels of sex steroids might have implications for CVD risk, and modification/intervention of these hormone levels might be of future interest in the prevention of CVD.
Our results might seem at odds with intervention trials in women, indicating reduced risk for CVD after hormone replacement therapy (HRT) initiated soon after menopause. Metaanalyses indicate about 30% reduced risk for CHD events (31) and 40% reduced total mortality (32) during HRT initiated before the age of 60 yr, compared with placebo. In contrast, the first report from the Women's Health Initiative (WHI) showed an initial increase in risk of CVD events in elderly women starting HRT (mean age about 63 yr) (33). However, the results from the first WHI report have no relevance to findings in the present study. The initial increased CVD risk in WHI results most likely from a mismatch between a high HRT dose for that age and the condition of the artery system in some of these elderly women likely to have various degree of atherosclerosis. Later reports from WHI show reduced coronary artery calcification (34) and 30% reduced total mortality (35) during HRT initiated before the age of 60 yr, compared with placebo.
There might be alternative explanations/interpretations of the results in the present study. First, there might a true association between steroid concentrations and prevalent CVD. Alternatively, lower androgen precursors early in the pathway and increased aromatase activity (E2/T) increasing estrogen levels in subjects with prevalent CVD might represent a response of the body to a diseased artery system, tentatively as an attempt to counteract the atherosclerotic process. In the present study, we found higher aromatase index (E2/T), favoring synthesis of estrogens from androgens and most likely contributing to the lower androgen precursors in both men and women with prevalent CVD. Furthermore, the E2 to E1 ratio was higher in subjects with prevalent CVD (significantly so in women), pushing for synthesis of E2, the more potent form of estrogen. Aromatase enzyme is present in most tissue, including the artery wall (36, 37). Furthermore, aromatase enzyme is present in the coronary artery wall and located in the vicinity of atherosclerotic plaques. Local aromatization of androgens to estrogens therefore seem important for protection against atherosclerosis (36). Recently Maggio et al. (38) found a positive association between serum E2 concentrations and inflammation, the inflammatory marker Il-6. One mechanism in counteracting the atherosclerotic process might be that estrogens moderate the inflammatory response, as has been a suggested action of estrogens in the brain (39). Therefore, instead of a simple causal relationship between endogenous steroid concentrations and prevalent CVD in our data on elderly, we suggest the alternative interpretation. The findings in the present study might represent the body's response to a deranged vascular system, with changes in endogenous steroid concentrations aimed to protect/repair the artery wall against further development toward atherosclerosis.
Study limitations
Our study addresses only 70-yr-old subjects, which limits the generalizability. The sample size of 202 subjects, with relatively few subjects with prevalent CVD, might seem small. However, some of the studies referred above were larger (9, 11, 12, 40) , whereas other were smaller (7, 10). Furthermore, our results are significant and consistent with each other in relation the proposed interpretation/hypothesis. Power is a problem when you do not have significant results, less so when the results are significant and consistent. Nevertheless, our results need to be confirmed in future studies. The information about prevalent CVD was based on medical history only and not on a proper investigation, which most likely would have increased the number of subjects with a diagnosis. The CVD categories presented in this study may overlap to include another CVD category. Because of the relatively small sample size, further analyses involving the exclusion of subjects with combined CVD diagnoses were not performed. However, the consistency in findings with regard to prevalent CVD, in both women and men, strengthens the credibility of our findings and the proposed hypothesis.
Conclusions
Prevalent CVD was associated with lower concentrations of androgen precursors, indications for increased aromatase activity, and with increased estrogen synthesis in both sexes. In women, these findings disagree with documented beneficial effects of HRT initiated soon after menopause, reducing the risk of CVD. Therefore, alternatively to a causative relationship, our findings might suggest existence of an endogenous hormonal response to developing atherosclerosis with a push toward androgens that are further aromatized to estrogens in an attempt to protect/repair the vascular system. Although our results are robust and internally consistent, due to the overall small number of subjects with CVD, confirmation in larger studies is needed. In addition, prospective evaluations, in which the relationships might be the opposite, are needed with regard to endogenous steroid hormone concentrations and coming risk of CVD events in elderly women and men.
